Detalhe da pesquisa
1.
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
N Engl J Med
; 384(25): 2394-2405, 2021 06 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34081848
2.
Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41.
Breast Cancer Res Treat
; 199(2): 243-252, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36944848
3.
Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer.
Breast Cancer Res Treat
; 192(1): 153-161, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35112166
4.
Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology).
Breast Cancer Res Treat
; 193(3): 555-564, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35230585
5.
A qualitative study to evaluate physician attitudes regarding omission of surgery among exceptional responders to neoadjuvant systemic therapy for breast cancer (NRG-CC006).
Breast Cancer Res Treat
; 187(3): 777-784, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33740205
6.
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 20(1): 88-99, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30509771
7.
Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination.
Breast Cancer Res Treat
; 178(2): 389-399, 2019 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-31428908
8.
Correction to: Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology).
Breast Cancer Res Treat
; 193(3): 565, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35507135
9.
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
Lancet Oncol
; 14(12): 1183-92, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24095300
10.
Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial.
Clin Cancer Res
; 30(9): 1984-1991, 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38376912
11.
Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer.
J Clin Oncol
; 42(11): 1288-1300, 2024 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38301187
12.
Talking numbers: how women and providers use risk scores during and after risk counseling - a qualitative investigation from the NRG Oncology/NSABP DMP-1 study.
BMJ Open
; 13(11): e073138, 2023 11 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37984961
13.
Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer.
J Natl Cancer Inst
; 115(11): 1302-1309, 2023 11 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37184928
14.
NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response.
Clin Cancer Res
; 26(16): 4233-4241, 2020 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32371537
15.
Regression on quantile residual life.
Biometrics
; 65(4): 1203-12, 2009 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-19432781
16.
Exploring Explanatory Models of Risk in Breast Cancer Risk Counseling Discussions: NSABP/NRG Oncology Decision-Making Project 1.
Cancer Nurs
; 42(1): 3-11, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-28661894
17.
Understanding Decision Making about Breast Cancer Prevention in Action: The Intersection of Perceived Risk, Perceived Control, and Social Context: NRG Oncology/NSABP DMP-1.
Med Decis Making
; 39(3): 217-227, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30803311
18.
Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer.
J Natl Cancer Inst
; 111(8): 867-871, 2019 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30888406
19.
Chemotherapy-Associated Peripheral Neuropathy in Patients With Early-Stage Breast Cancer: A Systematic Review.
J Natl Cancer Inst
; 110(2)2018 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28954296
20.
Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30.
J Natl Cancer Inst
; 110(2)2018 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28954297